Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : CSC-DC009198
Host Cell : HEK293 (Hela and other cell types are also available) Validation : Real-Time RCR
| Cat. No. | CSC-DC009198 |
| Description | Creative Biogene's Knockdown Cell Lines are target specific shRNA lentivirus transduced cells. The percent knockdown levels range from 75-99% depending on the gene, as evaluated by Real-Time RCR. Cells are rigorously qualified and mycoplasma free. |
| Target Gene | MAPK14 |
| Host Cell | HEK293 (Hela and other cell types are also available) |
| Host Cell Species | Homo sapiens (Human) |
| Applications |
(1) Studying gene functions (2) Studying gene interactions and signaling pathways (3) Target validation and drug discovery (4) Designing diseases models |
| Size | >1 × 106 cells / vial |
| Stability | Validated for at least 10 passages |
| Validation | Real-Time RCR |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Storage | Liquid Nitrogen |
| Shipping | Dry Ice |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
| Gene Name | MAPK14 mitogen-activated protein kinase 14 [ Homo sapiens ] |
| Gene Symbol | MAPK14 |
| Synonyms | MAPK14; mitogen-activated protein kinase 14; CSBP1, CSBP2, CSPB1; Mxi2; p38; p38 MAP kinase; PRKM14; PRKM15; MAP kinase 14; p38alpha Exip; MAP kinase Mxi2; MAP kinase p38 alpha; CSAID-binding protein; Csaids binding protein; MAX-interacting protein 2; stress-activated protein kinase 2A; p38 mitogen activated protein kinase; mitogen-activated protein kinase p38 alpha; cytokine suppressive anti-inflammatory drug binding protein; cytokine suppressive anti-inflammatory drug-binding protein; RK; CSBP; EXIP; CSBP1; CSBP2; CSPB1; SAPK2A; p38ALPHA; |
| GeneID | 1432 |
| Uni ProtID | Q16539 |
| mRNA Refseq | BC000092 |
| Chromosome Location | 6p21.3-p21.2 |
| Pathway | ADP signalling through P2Y purinoceptor 1, organism-specific biosystem; ATF-2 transcription factor network, organism-specific biosystem; Activated TLR4 signalling, organism-specific biosystem; Activation of the AP-1 family of transcription factors, organism-specific biosystem; Amyotrophic lateral sclerosis (ALS), organism-specific biosystem; Amyotrophic lateral sclerosis (ALS), conserved biosystem; Angiopoietin receptor Tie2-mediated signaling, organism-specific biosystem; |
| MIM | 600289 |
Mitogen-activated protein kinase 14 (MAPK14) plays a crucial role in DNA damage and repair and can be activated by various environmental stresses and pro-inflammatory cytokines. It is highly active in many tumors, acting as both a tumor promoter and a tumor suppressor, but its role in clear cell renal cell carcinoma (ccRCC) remains unclear. Cell cycle phosphatase 25B (CDC25B) is involved in cell cycle regulation and is highly expressed in many malignant tumors. Here, researchers analyzed the transcriptional levels of MAPK14 and CDC25B in 72 pairs of ccRCC and adjacent normal tissue samples from The Cancer Genome Atlas database, as well as the protein expression levels of MAPK14 and CDC25B in 66 pairs of clinical samples. Knockdown of MAPK14 reduced the protein levels of phosphorylated MAPK14 (P-MAPK14) and CDC25B. Subsequent Western blot and co-immunoprecipitation experiments showed that P-MAPK14 can bind to CDC25B, potentially maintaining its stability. Knockdown of MAPK14 inhibited the proliferation and migration of ccRCC cell lines, but this inhibition was partially reversed by overexpression of CDC25B. These results suggest that downregulation of MAPK14 and P-MAPK14 may inhibit ccRCC proliferation and migration by downregulating CDC25B.
To further investigate the biological function of MAPK14 in clear cell renal cell carcinoma (ccRCC), researchers used the CCK-8 assay to detect the activity of MAPK14 knockdown cells. The results showed that the activity of MAPK14-knockdown ACHN and CAKI-1 cells was significantly reduced compared to the control group (Figure 1A). EdU assay results indicated that cell proliferation capacity was significantly decreased after MAPK14 knockdown (Figure 1B). These results suggest that knocking down MAPK14 can inhibit the activity and proliferation of ccRCC cells in vitro. Furthermore, the migration ability of MAPK14-knockdown ACHN and CAKI-1 cells was significantly reduced (Figure 1C). Since the upregulation of E-cadherin and downregulation of N-cadherin have been confirmed to be associated with decreased cell migration ability, the researchers used Western blot to detect the expression of E-cadherin and N-cadherin after MAPK14 knockdown to further verify this observation. In MAPK14-knockdown cells, the expression of E-cadherin was significantly upregulated compared to the control group, while the expression of N-cadherin was significantly downregulated (Figure 1D). These results suggest that MAPK14 may play an important role in cell activity, proliferation, and migration.
Figure 1. Downregulation of MAPK14 inhibited cell activity, proliferation, and migration. (Liu J, et al., 2020)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.